Armata Pharmaceuticals Long Term Debt

Armata Pharmaceuticals (ARMP) currently reports a long-term debt of $370M as of March 2026. That compares with $27M in the prior-year period — up 1246.2% year over year. Use the charts on this page to explore Armata Pharmaceuticals's long-term debt history and peer comparisons.

Armata Pharmaceuticals's long-term debt increased from $27M to $370M — a 1246.2% year-over-year increase (period ending March 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Armata Pharmaceuticals reported $370M in long-term debt as of March 2026. That compares with $27M in the prior-year period — up 1246.2% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current long-term debt of $370M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Armata Pharmaceuticals, and consider following ARMP for alerts when major investors trade the stock.

Armata Pharmaceuticals is classified in the Healthcare sector. On long-term debt, it currently shows $370M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing ARMP with unrelated industries.